Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
by Barco, Stefano (Author)
, Voci, Davide (Author)
, Held, Ulrike (Author)
, Sebastian, Tim (Author)
, Bingisser, Roland (Author)
, Colucci, Giuseppe (Author)
, Dürschmied, Daniel (Author)
, Frenk, André (Author)
, Gerber, Bernhard (Author)
, Götschi, Andrea (Author)
, Konstantinides, Stavros V (Author)
, Mach, François (Author)
, Robert-Ebadi, Helia (Author)
, Rosemann, Thomas (Author)
, Simon, Noemi R (Author)
, Spechbach, Hervé (Author)
, Spirk, David (Author)
, Stortecky, Stefan (Author)
, Vaisnora, Lukas (Author)
, Righini, Marc (Author)
, Kucher, Nils (Author)
,
Call Number:
Loading…
Located:
Loading…
Article (Journal)
Online Resource